Skip to main contentSkip to navigation
Sirius Investors
Valion Bio, Inc.

Valion Bio, Inc.

VBIO
NASDAQHealthcare

Valion Bio, Inc. (VBIO) Investment Research Dashboard

About Valion Bio, Inc. (VBIO) stock analysis

Get live VBIO stock price $0.28, comprehensive Valion Bio, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time VBIO stock data and investment insights.

0.28
1.10%Today
Market Cap
894.95K
Volume
138.97K
52W High
5.60
52W Low
0.25

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Ne...

Company Information

CEO
Michael R. Cavanaugh
Sector
Healthcare
Industry
Biotechnology
Employees
52

Contact Information

Address
1305 E. Houston Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Listed on major US exchange (NASDAQ) providing liquidity and transparency

Higher growth potential with elevated volatility (Beta: 1.83)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Valion Bio, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Valion Bio, Inc.
  • Investors should consider how Valion Bio, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

894.95K

P/E Ratio (TTM)

-0.13

Beta

1.83

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

73/100 ⭐⭐⭐⭐⭐

Overall
+0.6%
NYSE
+0.7%
NASDAQ
+0.4%
Sector1D1W1MP/EScore
Financial Services+1.9%+2.8%+4.0%19.2
98/100⭐⭐⭐⭐⭐
Communication Services+1.5%-0.5%+3.1%22.3
74/100⭐⭐⭐⭐⭐
Healthcare+0.6%+1.2%+1.5%24.0
73/100⭐⭐⭐⭐⭐
Basic Materials+0.9%+1.7%+0.2%25.3
66/100⭐⭐⭐⭐
Consumer Defensive-0.0%+2.0%+0.9%29.8
63/100⭐⭐⭐⭐
Real Estate+0.4%+0.9%-1.6%29.5
50/100⭐⭐⭐
Energy-1.7%-3.3%-3.7%19.2
39/100⭐⭐
Utilities-1.1%-0.0%-4.5%26.8
35/100⭐⭐
Industrials+0.7%+0.5%-9.8%30.0
21/100
Technology+0.9%-1.3%-6.9%40.9
18/100
Consumer Cyclical+0.3%-1.7%-6.0%42.8
14/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.